Success Metrics

Clinical Success Rate

83.3%

Based on 5 completed trials

Completion Rate

83%(5/6)

Active Trials

0(0%)

Results Posted

80%(4 trials)

Terminated

1(13%)

Phase Distribution

Ph phase_2

25%

Ph phase_1

25%

Ph phase_3

13%

Ph phase_4

38%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

2(25.0%)

Phase 2Efficacy & side effects

2(25.0%)

Phase 3Large-scale testing

1(12.5%)

Phase 4Post-market surveillance

3(37.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Terminated(3)

Detailed Status

Completed5

Withdrawn2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

83.3%

Most Advanced

Phase 4

Trials by Phase

Phase 12 (25.0%)

Phase 22 (25.0%)

Phase 31 (12.5%)

Phase 43 (37.5%)

Trials by Status

terminated113%

withdrawn225%

completed563%

Recent Activity

0 active trials

Showing 5 of 8

terminatedphase_3

Clinical Trials (8)

Showing 8 of 8 trials

NCT02390284Phase 3

Stop Retinal Ganglion Cell Dysfunction Study

Terminated

NCT06312800Phase 2

Acamprosate and Methazolamide for Essential Tremor

Withdrawn

NCT02463357Phase 4

Three New Ideas to Protect Special Forces From the Stress of High Altitude

Completed

NCT00257829Phase 2

Improving Tumor Oxygenation in Cervical Cancer

Withdrawn

NCT02758470Phase 4

Muscle Fatigue and Carbonic Anhydrase Inhibitors

Completed

NCT01587027Phase 1

Safety Evaluation of Aminophylline and Methazolamide

Completed

NCT02760121Phase 4

AZ, MZ, and the Pulmonary System Response to Hypoxia

Completed

NCT01702025Phase 1

Rapid Acclimatization to Hypoxia at Altitude

Completed

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8